CD274 and neoplasm: Overall, the observed tumoral upregulation of PD-L1 and downregulation of Her-2/neu expression, based on the comparison of the same vaccine in both preclinical and clinical settings, is clinically relevant for the elimination of tumor cells with a PD-L1-positive/Her-2/neu-negative status, preventing new metastasis and immune evasion.